Samsung Biologics has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK, securing its first U.S.-based manufacturing site.
The Rockville, Md., facility includes two current good manufacturing practice-compliant plants with a combined 60,000 liters of drug substance capacity, according to a Dec. 22 news release. Samsung Biologics plans to expand the site’s capacity and upgrade its technology while continuing to produce existing products.
The $280 million acquisition is expected to close toward the end of the first quarter of 2026.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
